| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LRTM1 |
| Uniprot No | Q9HBL6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-345aa |
| 活性数据 | MKGELLLFSSVIVLLQVVCSCPDKCYCQSSTNFVDCSQQGLAEIPSHLPPQTRTLHLQDNQIHHLPAFAFRSVPWLMTLNLSNNSLSNLAPGAFHGLQHLQVLNLTQNSLLSLESRLFHSLPQLRELDLSSNNISHLPTSLGETWENLTILAVQQNQLQQLDRALLESMPSVRLLLLKDNLWKCNCHLLGLKLWLEKFVYKGGLTDGIICESPDTWKGKDLLRIPHELYQPCPLPAPDPVSSQAQWPGSAHGVVLRPPENHNAGERELLECELKPKPRPANLRHAIATVIITGVVCGIVCLMMLAAAIYGCTYAAITAQYHGGPLAQTNDPGKVEEKERFDSSPA |
| 分子量 | 64.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下提供的文献为示例参考结构，并非真实存在的论文。若需引用实际文献，建议通过学术数据库检索(如PubMed、Google Scholar)。以下是模拟示例：
---
1. **"Expression and Functional Characterization of Recombinant Human LRRTM1 in Synaptic Adhesion"**
*Author: Smith J et al. (2021)*
摘要：本研究成功在大肠杆菌系统中表达了重组人LRRTM1蛋白，验证其与神经配体neurexin的相互作用，并证明其在体外模型中促进神经元突触形成的能力。
2. **"Structural Insights into LRRTM1: A Cryo-EM Study of Recombinant Protein Dynamics"**
*Author: Chen L et al. (2019)*
摘要：通过冷冻电镜解析重组LRRTM1胞外结构域的构象变化，揭示其亮氨酸重复序列在跨突触信号传递中的关键作用，为自闭症相关突变研究提供依据。
3. **"LRRTM1 Knockdown and Recombinant Rescue in Cortical Neurons: Implications for Schizophrenia"**
*Author: Park S et al. (2018)*
摘要：利用重组LRRTM1蛋白恢复基因沉默神经元的突触功能，证实其在精神分裂症模型中的潜在治疗价值，并探讨其与谷氨酸受体结合的分子机制。
---
**注意**：上述文献标题及内容为虚构示例，实际研究中请使用专业数据库检索关键词如 **"recombinant human LRRTM1"**、**"LRRTM1 protein function"** 或结合具体研究领域(如神经突触、疾病模型)获取真实文献。
**Background of Recombinant Human LRRTM1 Protein**
Leucine-rich repeat transmembrane protein 1 (LRRTM1) belongs to a family of synaptic cell adhesion molecules characterized by extracellular leucine-rich repeat (LRR) domains and a single transmembrane domain. It is predominantly expressed in the central nervous system, where it plays a critical role in synapse formation, plasticity, and maintenance. LRRTM1 interacts with presynaptic neurexins, facilitating trans-synaptic signaling and promoting excitatory synapse development. Dysregulation of LRRTM1 has been implicated in neurodevelopmental disorders, including autism spectrum disorders and schizophrenia, highlighting its functional significance in neural circuitry.
Recombinant human LRRTM1 protein is engineered to mimic the native protein's structure and function. Produced using heterologous expression systems (e.g., mammalian or insect cells), it retains key domains required for ligand binding and synaptic activity. This recombinant tool enables researchers to study LRRTM1's mechanistic roles in vitro and in vivo, such as its involvement in synaptic adhesion, receptor clustering, and signaling pathways. Additionally, it serves as a potential therapeutic candidate for modulating synaptic connectivity in neurological diseases.
Current research focuses on mapping LRRTM1's interaction networks, exploring its post-translational modifications, and evaluating its therapeutic potential. Its recombinant form has become indispensable for structural studies, antibody development, and drug screening aimed at neurodegenerative and psychiatric disorders.
×
